| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10009465 | HBV | ENSG00000130707.18 | protein_coding | ASS1 | No | No | 445 | P00966 Q5T6L4 |
| TVIS10036839 | HBV | ENSG00000130707.18 | protein_coding | ASS1 | No | No | 445 | P00966 Q5T6L4 |
| TVIS10062550 | HBV | ENSG00000130707.18 | protein_coding | ASS1 | No | No | 445 | P00966 Q5T6L4 |
| TVIS30088707 | HIV | ENSG00000130707.18 | protein_coding | ASS1 | No | No | 445 | P00966 Q5T6L4 |
| TVIS30072166 | HIV | ENSG00000130707.18 | protein_coding | ASS1 | No | No | 445 | P00966 Q5T6L4 |
| TVIS20065430 | HPV | ENSG00000130707.18 | protein_coding | ASS1 | No | No | 445 | P00966 Q5T6L4 |
| TVIS20034622 | HPV | ENSG00000130707.18 | protein_coding | ASS1 | No | No | 445 | P00966 Q5T6L4 |
| TVIS44022964 | HTLV-1 | ENSG00000130707.18 | protein_coding | ASS1 | No | No | 445 | P00966 Q5T6L4 |
| TVIS44040355 | HTLV-1 | ENSG00000130707.18 | protein_coding | ASS1 | No | No | 445 | P00966 Q5T6L4 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | ASS1 |
|---|---|
| DrugBank ID | DB00128 |
| Drug Name | Aspartic acid |
| Target ID | BE0000671 |
| UniProt ID | P00966 |
| Regulation Type | |
| PubMed IDs | 17139284; 17016423; 17869551; 2791302; 15588718 |
| Citations | Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.@@Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.@@Flam BR, Eichler DC, Solomonson LP: Endothelial nitric oxide production is tightly coupled to the citrulline-NO cycle. Nitric Oxide. 2007 Nov-Dec;17(3-4):115-21. Epub 2007 Aug 3.@@Ben-Yoseph Y, Mitchell DA: Detection of kinetically abnormal argininosuccinate synthase in neonatal citrullinemia by conversion of citrulline to arginine in intact fibroblasts. Clin Chim Acta. 1989 Aug 15;183(2):125-33.@@Shen LJ, Beloussow K, Shen WC: Accessibility of endothelial and inducible nitric oxide synthase to the intracellular citrulline-arginine regeneration pathway. Biochem Pharmacol. 2005 Jan 1;69(1):97-104. |
| Groups | Approved; Nutraceutical |
| Direct Classification | Aspartic acid and derivatives |
| SMILES | N[C@@H](CC(O)=O)C(O)=O |
| Pathways | Lesch-Nyhan Syndrome (LNS); Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency); Xanthinuria Type I; Hyperornithinemia with Gyrate Atrophy (HOGA); Purine Nucleoside Phosphorylase Deficiency; Carnosinuria, Carnosinemia; Tyrosine Metabolism; Disulfiram Action Pathway; Hyperprolinemia Type II; Glutamate Metabolism; Adenine Phosphoribosyltransferase Deficiency (APRT); Mercaptopurine Action Pathway; Argininosuccinic Aciduria; L-Arginine:Glycine Amidinotransferase Deficiency; Xanthine Dehydrogenase Deficiency (Xanthinuria); Tyrosinemia Type I; Hyperinsulinism-Hyperammonemia Syndrome; Arginine: Glycine Amidinotransferase Deficiency (AGAT Deficiency); Mitochondrial DNA Depletion Syndrome; Creatine Deficiency, Guanidinoacetate Methyltransferase Deficiency; Carbamoyl Phosphate Synthetase Deficiency; Hyperprolinemia Type I; Myoadenylate Deaminase Deficiency; Homocarnosinosis; Malate-Aspartate Shuttle; Arginine and Proline Metabolism; Purine Metabolism; Gout or Kelley-Seegmiller Syndrome; Adenylosuccinate Lyase Deficiency; Ammonia Recycling |
| PharmGKB | PA448494 |
| ChEMBL | CHEMBL274323 |
